^(166)Ho-、^(153)Sm-聚氨基葡糖:理想的内照射治疗药物  

^(166)Ho- or ^(153)Sm-chitosan complex: an ideal inter-radiation drug

作　　者：尹其华[1] 刘璐(审校)[2] 王学斌(审校)[3] 

机构地区：[1]东南大学核医学技术研究所，南京210009 [2]东南大学核医学技术研究所 [3]北京师范大学化学系

出　　处：《国外医学（放射医学核医学分册）》2003年第6期245-247,共3页Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)

基　　金：江苏省卫生厅科研基金资助课题(H200117)

摘　　要：聚氨基葡糖作为载体与放射性核素166Ho或者153Sm螯合成复合物,通过间质给药后,主要滞留于注射部位的病变组织,通过辐射损伤达到治疗目的,而其他组织器官分布较少,是一种理想的内照射治疗药物。As a carrier, chitosan may form a compound 166Ho-CHICO, 153Sm-CHICO with 166Ho or 153Sm. Most of the compound retains in the lesional tissue of the injection site by the interstitial administration, while the distribution of the compound in other tissue and organ is less. Using radiation injury will achieve to the treatment purpose. The complex is regarded as an ideal inter-radiation drug.

关 键 词：^(166)Ho-聚氨基葡糖 ^(153)Sm-聚氨基葡糖 内照射疗法 肿瘤 类风湿性膝关节炎 

分 类 号：R817.9[医药卫生—影像医学与核医学]